NCT03268382Phase 2Completed

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Study sponsor: Aprea Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2019-07-10Actual
Enrollment · participants36Actual
Source updated2025-03-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.